Scientists Explore Potential and Challenges of New Technologies at Savannah Research Conference

For the first time, the Cystic Fibrosis Foundation invited non-CF experts to its annual research conference to meet with CF researchers. The conference -- New Technologies Advancing Toward a One-Time Cure -- in Savannah last month focused on the challenges being faced in gene editing, gene delivery and stem-cell biology and laid the foundation for new collaborations.

July 25, 2016 | 4 min read
Katherine Tuggle, Ph.D.

When the Cystic Fibrosis Foundation first set out to find and develop CFTR modulators in the late 1990s, researchers were optimistic but weren't quite sure whether this strategy would work. Although this research eventually led to the development of ivacaftor (Kalydeco®) and lumacaftor/ivacaftor (Orkambi®), the development of these medications was hardly guaranteed.

You may not follow science, but it's hard to escape the sunny news about gene editing these days. Although many of these stories highlight the amazing technology and its potential to change the lives of many living with genetic diseases, these stories don't often go into what it will take to turn these technologies into treatments. 

As we have been discovering, it's going to take a lot of collaboration among many disciplines to discover a way to correct the cystic fibrosis gene. Not only do we have to perfect the gene editing technology, we have to find the right vehicle to deliver it to the right cells in the lung. 

That's why we decided to bring together researchers from the worlds of gene editing, gene delivery and stem-cell biology with long-standing CF researchers for a first-of-its-kind conference -- New Technologies Advancing Toward a One-Time Cure.

Researchers tend to be very specialized and focused primarily on the intricacies of their research. So we organized the conference in Savannah, Ga., in a way that brought scientists with these different backgrounds into one room so they could begin to learn more about these other topics and where they have the potential to complement or overlap with each other. Instead of picking from a menu of multiple presentations, everyone went to the same presentations together in the same room. They ate breakfast, lunch and dinner together. They looked at each other's poster presentations, learning about their latest findings.

In the process, they learned what barriers each field faces and how those barriers could affect what they are doing and talked about ways to overcome those obstacles. 


For example, gene delivery researchers are perfecting ways to deliver gene editing tools into cells using viruses that are harmless to humans. Some of these viruses, however, are too small to carry the tools needed to edit the CF gene. Picture trying to carry a couch in a Mazda Miata. 

By learning about the size issues early in the process, gene delivery researchers can find a virus that is large enough to handle the load or gene editing researchers can develop smaller tools. 

As these fields advance in parallel, it is also important for the stem-cell biologists to speak with the gene delivery researchers so they can make sure that the delivery vehicles can target the right cells in the airway. All of this knowledge will have to come together when the tools are ready to be tested.

We scheduled an afternoon to enable like-minded researchers to discuss specific topics and to prioritize research questions that should be addressed in the short term. They also could identify potential barriers to developing these technologies into new therapies for people with CF. 

Following these small group discussions, we brought the entire group back together to review the smaller discussions and to get input from others. By the end of the meeting, I overheard numerous conversations about new collaborations because people found out about a technology or research approach that they wanted to integrate into their program back home. 

As people left the meeting, there was a sense of excitement and energy that I had not previously felt. I'm told this feeling is reminiscent of the research conferences in which CFTR modulators were first discussed. In Savannah, there was a general feeling of "we can do it," and these are the people who can make it happen. 

Now it's time for us to get to work. 

This site contains general information about cystic fibrosis, as well as personal insight from the CF community. Opinions and experiences shared by members of our community, including but not limited to people with CF and their families, belong solely to the blog post author and do not represent those of the Cystic Fibrosis Foundation, unless explicitly stated. In addition, the site is not intended as a substitute for treatment advice from a medical professional. Consult your doctor before making any changes to your treatment.

Share this article
Research | Our Research Approach

Katherine has been involved with CF research since 2009 as both a graduate student and postdoctoral fellow at the University of Alabama at Birmingham. In 2014, she joined the Foundation to oversee its basic science research programs, including the 11 basic science research centers around the country. She is also involved in a number of Foundation initiatives focused on developing and validating model systems that may be used for personalized medicine. In her free time, Katherine enjoys traveling with her husband and spending time with her German shepherd.

Recent Community Posts
Finding Stability in the Unknown
Blog | 6 min read
Advocating for Health Equity in Cystic Fibrosis
Blog | 6 min read
Organization Tips for Parents of Children With CF
Blog | 5 min read